A study on the relationship between blood levels of vascular endothelial growth factor and severity of diabetic retinopathy by Jebinth, Brayan
“A STUDY ON THE 
LEVELS OF 
FACTOR AND SEVERITY OF DIABETIC RETINOPATHY
In partial fulfillment of the requirements for the degree of
 
THE TAMILNADU DR.M.G.R.MEDICAL UNIVERSITY
DEPARTMENT OF OPHTHALMOLOGY
PSG INSTITUTE OF MEDICAL SCIENCES & RESEARCH
RELATIONSHIP BETWEEN 
VASCULAR ENDOTHELIAL GROWTH 
 
Dissertation submitted by 
DR. JEBINTH BRAYAN 
 
 
 
 
 
 
 
MASTER OF SURGERY 
IN 
OPHTHALMOLOGY 
 
APRIL 2016 
COIMBATORE
BLOOD 
” 
 
 
 
 
DECLARATION BY THE CANDIDATE 
 
I hereby declare that the dissertation titled ‘A STUDY ON THE 
RELATIONSHIP BETWEEN BLOOD LEVELS OF VASCULAR 
ENDOTHELIAL GROWTH FACTOR AND SEVERITY OF 
DIABETIC RETINOPATHY’ is a bonafide and genuine research work 
carried out by me under the guidance of Dr. D. SUNDAR, M.S,  D.O, 
Professor and Head of the Department of Ophthalmology, PSG Institute of 
Medical Sciences and Research, Coimbatore in partial for the award of 
M.S Degree in Ophthalmology to be held in 2016. This dissertation has not 
been submitted in part of full to any other University. This dissertation has 
not been submitted in part of full to any other University or towards any 
other degree before this mentioned date. 
 
 
 
 
 
 
Place: Coimbatore                                        Signature of the Candidate 
Date:  
 
CERTIFICATE BY THE GUIDE  
 
          This is to certify that the dissertation titled ‘A STUDY ON THE 
RELATIONSHIP BETWEEN BLOOD LEVELS OF VASCULAR 
ENDOTHELIAL GROWTH FACTOR AND SEVERITY OF 
DIABETIC RETINOPATHY’ is a bonafide and genuine research work 
done by Dr. JEBINTH BRAYAN, in partial fulfillment of the 
requirement for the degree of MASTER OF SURGERY IN 
OPHTHALMOLOGY as per regulations of PSG INTITUTE OF 
MEDICAL SCIENCES AND RESEARCH, COIMBATORE. I have 
great pleasure in forwarding this to the university.  
 
 
 
 
Place: Coimbatore              Dr. D. SUNDAR, M.S, D.O  
Date:                                              Professor and Head 
                                       Department of Ophthalmology 
PSG Institute of Medical Sciences 
and Research, Coimbatore 
 
ENDORSEMENT BY THE HEAD OF THE DEPARTMENT 
 
          This is to certify that the dissertation titled ‘A STUDY ON THE 
RELATIONSHIP BETWEEN BLOOD LEVELS OF VASCULAR 
ENDOTHELIAL GROWTH FACTOR AND SEVERITY OF 
DIABETIC RETINOPATHY’,  is a bonafide and Genuine research work 
done by Dr. JEBINTH BRAYAN under the guidance of   
Dr. D. SUNDAR MS, DO Professor, Department of Ophthalmology, PSG 
Institute of Medical Sciences and Research.  
 
 
 
 
 
Place: Coimbatore             Dr. D. SUNDAR, MS,DO 
Date:                      Professor and Head of the Department  
                                 PSG Institute of Medical Sciences  
and Research, Coimbatore 
  
ENDORSEMENT BY THE PRINCIPAL 
 
       This is to certify that the dissertation titled ‘A STUDY ON THE 
RELATIONSHIP BETWEEN BLOOD LEVELS OF VASCULAR 
ENDOTHELIAL GROWTH FACTOR AND SEVERITY OF 
DIABETIC RETINOPATHY’ is a bonafide and genuine research work 
done by Dr.JEBINTH BRAYAN under the guidance of  
Dr. D. SUNDAR, MS, DO, Professor and Head of the Department of 
Ophthalmology, PSG Institute of Medical Sciences and Research. 
 
 
 
 
 
Place: Coimbatore                     Dr. S. RAMALINGAM 
Date:                                       Principal 
                                                 PSG Institute of 
                                               Medical Sciences and Research 
Coimbatore 
  
COPYRIGHT 
DECLARATION BY THE CANDIDATE 
 
       I hereby declare that PSG Institute of Medical Sciences and Research, 
Coimbatore, shall have the rights to preserve, use and disseminate this 
dissertation in print or electronic format for academic/ research purposes. 
 
 
 
 
Place: Coimbatore                       Signature of Candidate 
Date:                                      Dr. JEBINTH BRAYAN 
 
 
 
 
 


  
ACKNOWLEDGEMENTS 
 
This project would not have been possible without the help of a number of 
people. 
I would like to thank my head of department and guide, Dr Sundar for allowing 
me the opportunity to do this study. 
I would like to thank Dr. Jeevamala, my co-guide, for her valuable suggestions 
and comments throughout study. 
From the depth of my heart, I thank Dr Alo for her skillful guidance and 
appreciable advices rendered to me throughout this work. She made it a highly 
successful one. 
I would like to thank Dr. B. Appalaraju, Head of Microbiology, for his 
invaluable help in the analysis of VEGF. I would also like to thank his team, Ms. 
Senthilkumari and Mr. Mohanakrishanan for patiently performing the laboratory tests 
for estimating the VEGF levels.  
I am grateful to Dr. Karthikeyan, for the help he gave me in the statistical 
analysis of my data.  
I would like to thank my sisters and colleagues,  Dr.Sanjana & Dr. Niranjana for 
helping me out, collecting blood samples etc. 
I would also like to thank my colleagues and staff in the department for their 
support.  
My acknowledgement will be incomplete if I do not thank my patients, all of 
whom agreed to take part in my research. Without them, definitely, none of this would 
have been possible. 
   
TABLE OF CONTENTS 
   
1. Introduction 1 
2. Aim 3 
3. Objectives  4 
4. Review of literature 5 
5. Materials and methods 51 
6. Results 55 
7. Discussion 65 
8. Conclusion 70 
9. Limitations 71 
10. Bibliography 72 
11. Annexure  97 
 
  
“A STUDY ON THE RELATIONSHIP BETWEEN BLOOD LEVELS OF 
VASCULAR ENDOTHELIAL GROWTH FACTOR AND SEVERITY OF 
DIABETIC RETINOPATHY” 
Dissertation by Dr. JEBINTH BRAYAN 
 
ABSTRACT 
BACKGROUND: The importance of vascular endothelial growth factor in (VEGF) the 
pathogenesis of diabetic retinopathy is evident from numerous studies demonstrating a 
significant increase in VEGF levels in ocular samples. However, a correlation between blood 
levels of VEGF and diabetic retinopathy has not been conclusively proven or disproven. We 
undertake this study to demonstrate the relationship between blood levels of VEGF and the 
severity of diabetic retinopathy.   
METHODS: The study population consisted of 75 Type 2 diabetic patients attending our 
outpatient department for routine diabetic retinopathy screening. After obtaining informed 
consent, 5ml of blood was drawn from each patient and estimated for the levels of serum 
VEGF. The data thus obtained was correlated with the grade of retinopathy. Additional 
parameters studied were duration of diabetes, haemoglobin levels, blood urea, serum 
creatinine, fasting and random blood sugars and HBA1C levels. 
RESULTS: There was a significant elevation of blood VEGF levels when compared to the 
normal population. But this elevation was seen in all the patients irrespective of whether they 
had retinopathy or not. There was no correlation detected between VEGF levels and the 
severity of diabetes. There was a positive association between anemia and the severity of 
retinopathy. The levels of urea and creatinine were elevated in the more severe grade of 
retinopathy. There was an overall poor control of sugars reflected both by the high levels of 
fasting and random sugars and the high HBA1C.       
CONCLUSION: Levels of blood VEGF are elevated in diabetic patients regardless of 
whether they have diabetic retinopathy or not. There is no statistically significant relationship 
between blood levels of VEGF and the severity of retinopathy. VEGF, therefore could 
present a potential treatment and preventive strategy for not only diabetic retinopathy but 
diabetes and its complications in general. 
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Introduction  
Diabetic retinopathy (DR) can be either a non-proliferative or a proliferative 
pathology of the retina. Either way, it is probably the most significant complication of a 
systemic disease in the eye.  Over a period spanning about half a century, the world has 
witnessed remarkable progress in the field of diabetic retinopathy (DR) and its 
management. From the early days of the Arlie house classification for staging of 
diabetic retinopathy, we have now entered firmly into the realm of anti-vascular growth 
factor (anti-VEGF) therapy.  
A review of the literature shows five major points of change in the field of  
DR. Firstly, diabetes and its complications have become a global problem; to the extent 
that DR has assumed the status of a global epidemic. Diabetic retinopathy has thus 
become the leading cause of blindness in the middle aged population. (1) Secondly, as 
proved by a number of randomized control trials, tight control of blood sugars and 
additional systemic co-morbidities play a major role in the disease progression. (2)(3). 
Thirdly, optical coherence tomography (OCT) has become a major component in DR 
staging and management. With the improved resolution of images, ophthalmologists 
can cut down on the use of fundus fluorescein angiography. Fourthly, timely retinal 
photocoagulation can protect the retina from developing end stage disease. And lastly, 
the role of vascular endothelial growth factor (VEGF) appears to be central to the 
pathogenesis of DR. Thus anti-VEGF therapy has become one of the first lines of 
treatment, especially of diabetic macular edema.     
The importance of VEGF in the disease pathogenesis was realized by the 
observation that the vitreous cavity of patients with DR had higher levels of VEGF than 
those of controls. To the best of our knowledge, all studies thus far, are mainly based 
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on measurements of VEGF in the vitreous cavity. (4)(5)(6)(7)(8).We aim to study the 
serum levels of VEGF in diabetic patients with DR and also the correlation, if any, 
between serum VEGF and the grading of DR. If such a correlation is found to exist, we 
believe it would have undeniable implications in the prognostication, monitoring and 
treatment of a disease capable of causing significant damage to an individual, a family 
and a nation, not to mention the whole world.  
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Aim  
 To establish a relationship between the serum levels of vascular endothelial 
growth factor and the severity of Diabetic Retinopathy. 
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Objectives 
Primary outcome 
1. Determine the serum VEGF levels in the study population of 75 patients of type 
2 diabetes mellitus. 
2. Determine whether this level is significantly altered with respect to normal 
ranges 
3. Determine a trend (if any) of the serum VEGF and severity of diabetic 
retinopathy. 
Secondary outcome 
1. Study the demographic characteristics of the study population.      
2. Determine the relationship between the duration of diabetes and the severity of 
retinopathy. 
3. Determine the relationship between urea, serum creatinine and the severity of 
retinopathy. 
4. Determine the relationship between fasting and random blood glucose and the 
severity of retinopathy 
5. Determine any association between HBA1C and the severity of diabetic 
retinopathy.  
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Review of literature 
Diabetes Mellitus- a global epidemic  
 Every seven seconds a person dies of a diabetes related complication(9). In 
1995, the prevalence of diabetes in the adult population was estimated to be 4%. It is 
estimated to become 5.4% by 2025. In absolute figures, the number of adult diabetics 
will rise from 135 million in 1995 to 300 million in 2025. (1) The bulk of this increase 
will be in the developing countries, where there is predicted to be a 170% increase in 
the number of diabetic patients. By 2025, more than 75% of these diabetics will be in 
developing countries. This is in contrast to the 62% reported in 1995. Data from a 
number of studies show that the diabetes epidemic will affect the middle and low 
economic countries, with these countries contributing as much as 77% of the diabetic 
population.(10)(11)(12) 
 The Global burden due to diseases in general,  is showing a shifting trend. 
Whereas, previously the major disease burden was due to communicable diseases, the 
trend nowadays seems to be shifting to noncommunicable disease.(13)(14)(15)(16)(17) 
In a study conducted by Lozano et al, there was a marked increase in the deaths due to 
diabetes. In their study conducted to estimate the Global Burden of diseases, injuries 
and risk factor, they reported 1.3 million diabetes related deaths- an almost doubling of 
the numbers seen in 1990. (15) The disability adjusted life years(DALY)  due to 
diabetes- a measure of the mortality due to a disease- is also on the rise. In a study, 
published in The Lancet 2013, there was a shift of the DALYs from communicable 
disease to non-communicable disease with a decrease in the number of premature 
deaths and an increase in persons living with disability. There was an increase in the 
burden due to a variety of diseases, diabetes being a major one.  
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Diabetes in India 
  The prevalence of diabetes among Asians has been rapidly increasing. As of 
2007, more than 110 million diabetics were from Asia.(18) Extrapolating from the 
current data available, the countries with the largest number of diabetic patients at 
present and in 2025 will be India, China and the United States. (1) As quoted in the 
study by Ramachandran et al, the national prevalence of diabetes has already doubled 
and more in a number of countries in this region. (11)  
Table 1. A review of data from South India,(19)(11)(20) 
 Prevalence Percentage increase 
 Urban  Rural  Urban  Rural  
1989 8.2% 2.4%   
2006 18.6% 9.2% 2.3% 3.8% 
  
   In a study conducted on an urban slum in North India, the prevalence of 
diabetes was 10.3%, with males having a prevalence of 11.2% and females a 
prevalence of 9.9%. (21) 
 One of the postulated reasons for the diabetes boom in countries such as India 
and China is said to be the rapid urbanization and economic growth in the recent years. 
This has in turn led to changes in the nutritional habits and an increasingly sedentary 
lifestyle. (10) Urbanization leads to a significant decrease in physical activity with a 
corresponding increase in the body mass index. (22); all being risk factors for the 
development and progression of diabetes.  
 Apart from the rising epidemic in Asian countries, the Asian diabetic seems to 
acquire diabetes at an earlier age and with a lower body mass index. (23),(11)(18) This 
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type of “metabolically obese” phenotype- normal body weight with increased 
abdominal adiposity- seems to be typical of the Asian. This, along with an increased 
susceptibility to gestational diabetes, poor nutrition in utero and overnutrition in adult 
years seems to be contributing to the diabetes epidemic, constituting a vicious cycle 
where “diabetes begets diabetes”.  (24)(18)(21)(11)(10) This younger age of onset and 
a longer duration of disease accordingly increases the morbidity and mortality 
associated with diabetes substantially.(24)(18)  
 Regardless, a worldwide surveillance of diabetes and its complications is 
necessary for its prevention and progression and should be given urgent priority in all 
parts of the world, regardless of whether they are developing or developed.(16)(14).  
Definition of Diabetes- 
  Diabetes Mellitus is an all-encompassing term to describe conditions of 
metabolic disturbance wherein the main feature is a chronic elevation in blood sugars. 
The chief cause is either an impaired insulin action or an impaired insulin secretion or 
both. (25)(26) 
 The gold standard for diagnosis of diabetes is a measurement of the glucose 
levels in venous plasma. For accurate measurement glycolysis must be inhibited in the 
sample as soon as the blood is drawn. This can be achieved in by either storing the 
blood tube in ice and centrifuging in 30 minutes, or by adding inhibitors of glycolysis 
into the tube such as citrate with fluoride. In our institution, we are using the former 
technique  
The guidelines for a diagnosis of DM are (25)(26)(27) 
• Random plasma glucose >= 200 mg/dl (>=11.1 mmol/l) 
8 
 
• Fasting >=126 mg/dl (>=7.0 mmol/dl) 
• HbA1c >=6.5% (>= 48 mmol/mol) 
• OGTT 2 hour glucose in venous plasma >=200 mg/dl (>= 11.1 mmol/l) 
For a diagnosis to be made, persistant blood glucose levels meeting the 
diagnostic levels must be demonstrated on two or more occasions on two separate 
daysw. 
A similar classification has also been proposed by the WHO. In addition, 
impaired glucose tolerance (IGT) have been assigned values that are above normal but 
below the diagnostic cutoffs for DM (plasma >=  6.1 to 7mmol/l)  
The inclusion of HbA1c in the diagnostic process has been there since 2010. 
Recent studies have shown that the specificity of Hba1c levels >=6.5% is high enough 
for a diagnosis of diabetes and the sensitivity of HbA1c <5.7% is enough to exclude a 
diagnosis of diabetes; making HbA1c a useful primary screening tool in the diagnosis 
of diabetes. 
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Table 2. Flowchart for diagnosis of diabetes using HBA1c as the primary screening 
tool (25) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
History suggestive of DM 
(LOA, polyuria, polydypsia, recurrent infections) 
Or increased diabetes risk. 
HBA1c 
>= 6.5% 5.7-6.5% 
<5.7% 
Fasting and 2 hour PP 
glucose 
Fasting >= 
126 and/or 
2h PP >=200 
Fasting 100-125 
and/or 2hr PP 140-199 Fasting <100 and PP <140 
and /or OGTT <100  fasting  
DIABETES 
NO DIABETES Work up of diabetic risk factors, life style, 
Treatment of the risk factors. 
Follow up assessment and HBA1c after 1 
year. 
Treatment according 
to protocol 
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Classification of DM (25)(26)(27)  
  Depending on the basic etiology, clinical features, age of onset and other factors 
DM can be broadly divided into the following 
 Type 1 Diabetes 
• Β-cell destruction leading to an absolute deficiency in insulin 
• Predominantly an immune mediated disease. 
• Latent autoimmune diabetes in adults (LADA) is included in this category. 
 
 Type 2 Diabetes 
• Ranges from mainly an insulin resistance with a relative insulin deficiency to a 
defective insulin secretion along with insulin resistance.  
• This type is very commonly associated with other problems constituting the 
metabolic syndrome. 
 
 Other specific types of Diabetes 
• Diabetes associated with disease of the pancreas (Pancreatitis, CF ) 
• Endocrine disorders (acromegaly, phaechromocytoma, cushings syndrome) 
• Drug induced  
• Genetic defects of the β-cells (MODY forms) 
• Genetic defects of insulin activity 
• Miscellaneous genetic syndromes which maybe associated with diabetes 
• Infections 
• Rare forms of auto-immune mediated diabetes. 
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 Gestational diabetes 
Table 3. Differentiating features between Type 1 and Type 2 diabetes (25) 
 Type 1 Diabetes Type 2 Diabetes 
Age of onset Mainly childhood, 
adolescents and young 
adults 
Mainly middle and old age 
Presentation Usually acute to subacute 
onset 
Usually gradual 
Symptoms Usually polyuria, 
polydipsia, weight loss and 
malaise 
Often no complaints 
Body weight Often normal or thinly 
built 
Frequently overweight 
Progression to 
ketoacidosis 
Marked None or slight 
Insulin secretion Reduced or no secretion Below normal to high, 
qualitatively always 
impaired 
Insulin resistance None (or only low) Pronounced 
Positive family history Usually none Typically positive 
Concordance with 
identical twins 
30-50% Over 50% 
Hereditary Multifactorial Multifactorial (likely to be 
polygenetic, but possible 
role for genetic 
heterogenicity) 
Association with HLA 
system 
Present Not present 
Antibodies associated with 
diabetic metabolism 
Present in 90-95% at onset None 
Metabolism Unstable Stable 
Response to insulin 
secretion stimulating 
antidiabetics 
Usually none Usually good at first 
Insulin therapy Needed Usually not needed until 
insulin secretion has 
decreased after many years 
of the disease. 
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 In addition to this classification, the report by the Japan Diabetes Society for the 
Classification and Diagnosis of Diabetes Mellitus advocate the importance of 
classifying the state of glycemia also, into normal, borderline and diabetic types. 
• Diabetic type- fasting plasma glucose >=126 mg/dl and or 2 hour PP after a 75g 
glucose load >= 200mg/dl. A random glucose >=200 mg/dl is also suggestive of 
diabetic type. 
• Normal type- fasting plasma glucose <110mg/dl and 2 hour PP <140 mg/dl 
• Borderline type are patients who don’t fall into either category. When OGTT is 
done, this type constitutes the sum of those with impaired fasting glycemia and 
impaired glucose tolerance. Patients with this type are more at risk for developing 
diabetes than the normal type. (27)(28) 
The complications of DM- 
The complications of DM are potentially disastrous and the importance of 
protecting the body from hyperglycemia cannot be overemphasized. These 
complications can be broadly divided into acute and chronic. The acute complications 
are chiefly due to severe hyperglycemia. This includes diabetic ketoacidosis and 
hyperosmolar nonketotic state. (29) 
The majority of the chronic complications of diabetes involve the vascular tree 
and this forms the bulk of the morbidity and mortality associated with both type 1 and 
type 2 diabetes.(30) 
Traditionally the chronic complications of diabetes have been divided into 
macrovascular and microvascular complications(29)(30)(31). 
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Table 4. Macro and microvascular complications of diabetes 
Macrovascular complications 
Coronary circulation Myocardial ischeamia/infarction 
Cerebral circulation Transient ischeamic attack, stroke 
Peripheral circulation Claudication, ischemia 
Microvascular complications/neuropathic 
Retinopathy, cataract Impaired vision 
Nephropathy Renal failure 
Peripheral neuropathy Sensory loss 
Motor weakness 
Autonomic neuropathy Postural hypotension 
GI problem 
Foot disease Ulceration 
Arthropathy  
 
Macrovascular complications of Diabetes- 
The central pathology of the macrovascular disease is atherosclerosis. This 
effectively results in a narrowing of the arterial vasculature all over the body. (32) 
Chronic inflammation and intravascular injury to the arterial vasculature in the 
peripheral and cardiac circulations leads to atherosclerosis. As an effect of this 
endothelial damage, oxidized lipids from LDL particles get deposited in the endothelial 
layer of the arterial wall. Monocytes then migrate to the site and phagocytose the lipids 
to form foam cells. After foam cells are formed, they stimulate further macrophage 
migration and also attract T-lymphocytes. The T-lymphocytes, in turn, stimulate the 
formation and proliferation of smooth muscle cellsand collagen accumulatiom. Finally 
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all this leads to the formation of a lipid-rich atherosclerotic plaque in the arterial wall. 
Rupture of this leads to acute vascular infarction. (33) 
Figure 1. Pathogenesis of arterial disease in DR 
  
The postulated link between Type 2 diabetes/insulin resistance and 
macrovascular disease includes a number of theories such as- reduced adiponectin 
concentration, increased formation of vascular cell adhesion molecule-1. These factors 
play a role in the T-lymphcyte adhesion to the endothelium. It also leads to a 
procoagulable state with increased expression of plasminogen activator inhibitor-1 
(PAI-1) with additional atherosclerotic plaque instability. (33) The deadly combination 
of increased coagulability with impaired fibrinolysis increases the likelihood of 
vascular occlusion and vascular complications associated with DM type 2. (34) 
The precise mechanism/s by which diabetes increases the risk of developing 
atheromatous plaque has not been clearly defined, the association between the two 
cannot be disputed.(30). There are a number of theories including the activation of the 
aldose reductase pathway, formation of an environment of elevated oxidative stress, 
advanced glycation end products, and the protein kinase c theory. 
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Of all the macrovascular complications, coronary heart disease is probably the 
most common cause of death and morbidity. This association between CAD and 
diabetes has been highlighted in a number of studies beginning with the Framingham 
study. (35) In fact, it has been shown in more recent studies that the risk of myocardial 
infarction in diabetic patients is equivalent to the risk in nondiabetics with one prior 
attack, promoting DM to a status of risk equivalent for CAD rather than just a risk 
factor. (36)(37). 
DM is also a strong predictive risk factor for stroke and peripheral vascular 
disease.  The risk of stroke in a diabetic is increased by 150-400%. (38). The frequency 
of stroke related complications such as dementia are likewise elevated in diabetics. 
(34). 
As mentioned above, DM often is present in a setting of metabolic disturbance. 
This metabolic syndrome includes obesity mainly of the abdominal variety, 
hypertension, hyperlipidemia, and hypercoagulabilty- all factors which can aggravate 
and promote vascular disease. Even so, diabetes can be considered as an independent 
risk factor for the development of ischeamic heart disease, CVD and even death. (39) 
Microvascular complications of diabetes mellitus 
Diabetic nephropathy- 
  Diabetic nephropathy by definition is proteinuria >500mg in 24 hours. However 
it is often preceded by degrees of proteinuria. This microalbuminuria is defined as an 
albumin excretion of 30-299mg in 24 hours. If left untreated, this microalbuminuria 
progresses to proteinuria and then frank diabetic renal failure. 
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In a study done by Gross et al, about 7% of diabetics have microalbuminuria at 
presentation. (40). According to the results published by the UKPDS, microalbuminuria 
had an annual incidence of 2% in type 2 diabetics and the prevalence after 10 years was 
25%. (40)(41) 
The pathological changes induced by diabetes in the kidney are increase in 
glomerular basement membrane thickness, microaneurysm formation, formation of 
Kimmelsteil-Wilson bodies (mesangial nodules) the underlying mechanism by which 
diabetes causes this is probably similar to the mechanism of diabetic retinopathy. 
Diabetic neuropathy 
  “The symptoms and/or signs of peripheral nerve dysfunction in diabetics after 
the exclusion of other causes” constitutes the definition of diabetic neuropathy by the 
American Diabetes Association. (42). The likelihood of developing neuropathy 
depends on both the degree and duration of elevated sugars. In addition, some 
individuals possess some genetic characteristics making them more susceptible.  
The eitiopathogenesis of peripheral neuropathy has not been elucidated, but 
several theories exist such as the role of polyol accumulation, oxidative stress injury 
and the role of AGE’s.  
The peripheral neuropathy can take several forms- sensory, focal/multifocal and 
autonomic neuropathies.  
Chronic sensorimotor, symmetric, polyneuropathy is the most commonly 
encountered type in diabetics. The patient can present with a variety of symptoms such 
as burning, “shock-like” sensations, tingling or just a numb feeling. But the type with 
just numbness can present with a non-healing ulcer. On examination there is a loss to 
light touch, vibration and temperature sensation. There is also a loss of the ankle 
17 
 
reflex.(43). Studies have shown that especially individuals with a loss of 10-g 
monofilament are at an increased risk of ulceration of the lower limb. (44).  
Mononeuropathies have a typical sudden onset and can involve any nerve. The 
most common nerves affected are the median, ulnar and radial nerves. In addition 
cranial nerves can also be affected. In electrophysiological tests there is a decrease both 
in the amplitude and the conduction of a nerve impulse. Severe pain, muscle weakness 
and atrophy, usually in the thigh, is called diabetic amyotrophy, and maybe a 
manifestation of mononeuropathy. 
Diabetic autonomic dysfunction can occur in almost any organ. It can manifest 
in a number of ways such as- gastroparesis, constipation, diarrhea, bladder and bowel 
problems, silent ischemia and even sudden death due to cardiac irregularities. Silent 
myocardial ischemia is a cause of significant mortality. (45). 
Diabetic retinopathy 
Global indices of diabetic retinopathy. 
 DR has now become a very real threat to the quality of life for millions a people 
worldwide.(46)(47)  The increasing prevalence of DR globally, mirrors the increase in 
the prevalence of diabetes. The number of people above 40 years of age in America to 
be affected by DR by the year 2050, is estimated to be 3.4 million.(46) This translates 
to $492 million loss towards direct medical treatment. In addition there are added costs 
due to lost wages and time. (46) 
Using pooled data from 35 studies on more than 20,000 people, Yau et al 
estimated that there are about 93 million people with DR, 17 million with proliferative 
diabetic retinopathy (PDR), 21 million with diabetic macular edema. (48). Among 
diabetics, the prevalence of any kind of DR was 34.6%, PDR was 7.0%, DME was 
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6.6% and VTDR 10.2%. In a study conducted in Caucasians aged more than 40 years 
with type 2 DM, showed an overall prevalence of 40% for any kind of DR and 8% for 
VTDR. (49).  
Taking a closer look at the epidemiological studies, the susceptibility to DR 
seems to vary among different ethnic groups. Higher prevalence of DR has been 
reported among Mexican Americans than in non-hispanic white people. (50)(51)(52). 
However, other studies have shown a lower prevalence of DR among African 
Americans and Mexican Americans than in non-Hispanic whites. (53)(54). There are a 
number of possible factors which could explain this ethnic difference in the rate and 
susceptibility to DR. a possible genetic susceptibility, socio-economic differences and 
access to medical care. There has also been speculation about a role for racial 
differences in the effect of DR risk factors. (55)(56).   
Interestingly, apart from the significant visual impairment caused by DR, 
evidence suggests that just the presence of DR increases the risk of systemic vascular 
complications such as CVA, CAD, heart failure and kidney disease. The converse also 
seems to be true. Diabetes duration, HbA1c levels and blood pressure all play an 
important part in DR, and this correlation applies all the way across mild to vision-
threatening stages of DR. (57)(58)(59)(60)(61). 
In the report by Yau et al, higher serum cholesterol levels were associated with 
elevated risk of diabetic macular edema. (48) This fact is further strengthened by 
another, that fenofibrate, a lipid-lowering agent, may retard the progression of DR.(62)  
The prevalence of DR is higher in Type 1 diabetics than in Type 2. This is independent 
of the duration of diabetes. (63)(64) 
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Figure 2. Epidemiological data from 35 studies on DR (48) 
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Diabetic retinopathy in India- 
 The burden of visual impairment in India is large and increasing. It is estimated 
that 1-1.5% of the Indian population are blind.(65)(66)(67) With a population 
exceeding 1 billion, this actually translates into huge numbers. DR is fast becoming a 
significant cause of visual pathology in India. (68) In the study by Dandona et al, on an 
urban population, of the total population studied, 1.8%  above 30 years of age, suffered 
from DR. in  the same study, DR was present in 22.4% of diabetics, self- reporting. 
(69). In another report carried out in a diabetes centre in South India, 34.1% of patients 
were reported to have DR. (70) 
Table 5. Self reported diabetes and diabetic retinopathy- Dandona et al 
 Males Females 
Self-reported diabetes 9.44% 6.49% 
Diabetic retinopathy 2.14% 1.49% 
  
In the above quoted study, most of the patients who had DR had mild or 
moderate Non proliferative diabetic retinopathy (NPDR)  (89.3%), severe NPDR and 
Proliferative diabetic retinopathy were relatively less common (10.7%).  A decrease in 
vision in either eye due to DR was present in a tenth of those with DR. No eye was 
blind due to DR in the population sample studied. This is in contrast to studies from 
developed countries, where a higher incidence of blindness has been reported. (71). The 
authors theorize that this could be due to the fact that in India, the diabetics die faster 
due to lack of adequate medical services.  Also, most of the patients in their study had 
DM diagnosed after 30 years of age. It is an established fact that chances of DR are 
more when the DM has been diagnosed less than 30 years of age. 
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 A study conducted in Kerala via a questionnaire distributed to self-reporting 
diabetics reports a 26.8% prevalence. (72). In a report from Chennai, the prevalence 
was 20.8%.  (73). Interestingly, the prevalence of DR among first time diagnosed 
diabetic patients was 5.1%- this is less than those reported by other Western studies 
where the prevalence of DR at the time of diagnosis was from 20-35%. (63)(74)(75). 
This seems to hold true even when the age factor has been removed, as has been shown 
in other studies, such as the Asian Young Diabetes Study, where they reported a lower 
prevalence of DR in Indians when compared to other Asian groups.  (76) 
Table 6. The difference in the prevalence of DR in different ethnic groups (77) 
Population Place Year 
Total 
diabetic 
population 
Prevalence of 
retinopathy in 
percentage 
Chennai Urban 
Rural 
Epidemiology 
Study (CURES)- 
eye study  1 
Chennai, India  2003 1715 17.6% 
Los Angeles Latino 
Eye Study 
(LALES) 
Los Angeles, 
USA 
1999-2003 1217 46.9 
The Liverpool 
Diabetic Study 
Liverpool, UK 1998 395 33.6 
Barbados eye study Barbados, west 
Indies 
1998 615 28.8 
Blue Mountains 
Eye Study  
Blue Mountain, 
Australia 
1992-1994 252 29.0 
Taiwan Taiwan, china 1991 527 35.0 
Beaver Dam Eye 
Study 
Wisconsin, 
USA 
1988-1990 410 35.1 
Wisconsin 
Epidemiologic 
Study of Diabetic 
Retinopathy 
Southern 
Wisconsin, 
USA 
1980-82 1313 50.3% 
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 The lower prevalence of DR in Indians, as seen in the above table, maybe due to 
an inherent ethnic difference. Another theory proposed is the Indian diet, which though 
high in carbohydrates, includes more vegetables, less fatty substances and more anti-
oxidants and anti-inflammatory substances. 
Risk factors for the development of diabetic retinopathy(77) 
Systemic factors                                            Ocular factors 
Gender                                                   Posterior vitreous detachment                     
Duration of DM                                               Old chorioretinopathy 
Level of glycaemic control                                   Cataract surgery  
Hypertension 
Associated nephropathy 
Altered lipid profile 
Pregnancy 
Alcohol 
Aneamia 
Obesity 
Gender-  
 There are conflicting reports on the association between gender and DR. in the 
Chennai study, DR seems to be more common in males as compared to female with a 
ratio of 2:1. (70)  
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Duration of disease- 
 All studies highlight the fact that duration of disease is strongly associated with 
increased prevalence and severity of DR. This has been shown in a number of Indian 
studies as well. (73)(69). In the study by Dandona et al, they reported an 87.5% 
prevalence of DR with those having DM for more than 15 years versus 18.9% for those 
with DM for less than 15 years. Also, it has been reported that for every five year added 
years of diabetes, the risk of DR is increased by 1.89.  
Glycaemic control-  
The benefits of maintaining strict control over the levels of sugars on the 
development and progression of DR has been emphasized in numerous studies. (63)(2). 
In the WESDR study, there was a 12% prevalence of DR when HbA1c levels were 
<7% versus 40.7% when HbA1c >10, in addition the chances of developing PDR with 
more severe retinal changes at baseline increased with the HbA1c levels. (63). Intensive 
therapy of sugars reduced ocular pathology by 54%, decreased the progression of 
NPDR to PDR or severe PDR by 47% and the requirement for laser by 56%. In the 
study by Remal et al, the final visual prognosis after laser photocoagulation was also 
dependant on the sugar control. 
Hypertension- 
 Hypertension can affect DR by impaired autoregulation and hyperperfusion 
(hemodynamic) and through vascular endothelial factor (VEGF). Ultimately it adds to 
the damage to the retinal capillary endothelial cells.(78) There is a worsening of DR by 
the added presence of hypertension. (79)(80). In the Indian scenario, hypertension has 
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not been conclusively shown to be a confounding factor for DR. But uncontrolled 
hypertension does effect DR. (73)    
Renal disease-  
 A number of studies have demonstrated a relationship between 
microalbuminuria, proteinuria and DR. (81)(82). This synergy between retinopathy and 
renal angiopathy maybe due to hypertension, increase fibrinogen levels and increased 
lipids. (83). Data from South India show a proteinuria in 29.2% of patients with DR. 
Studies from North India show an association between microalbuminuria and DR. 
(84)(85) 
Elevated serum lipids- 
 The risk of developing hard exudates is increased with elevated lipid levels. 
(86)(87)(3). Similar findings have been reported from studies done in India. Some have 
demonstrated a decrease in the size of perimacular hard exudates.  This is possibly due 
to an increase in pipid peroxidation in plasma. Significantly, macular edema showed an 
association with high LDL levels. (88)(89).  
Pregnancy- 
In Western literature, pregnancy has been shown to cause rapid progression of 
DR. However, this effect seems to be transient and the overall risk of progression is not 
increased by pregnancy. (90). Risk factors for progression include duration of diabetes, 
glucose control, the degree of retinopathy and the presence of other premorbid 
conditions. (91)There is a lack of Indian data on the behavior of DR in pregnancy.  
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Alcohol- 
 Heavy and prolonged alcohol intake has been associated with DR progression. 
(92) (93). However, in another study by Moss et al showed no significant association. 
(94) 
Anemia-  
 A report by Singh et al reported spontaneous regression by microaneurysms by 
correction of anemia.(95) It is possible that co-existing anemia worsens DR by 
delivering small amounts of oxygen to already ischemic retinal tissue. (96) As 
demonstrated by the ETDRS, anemia was a risk factor for developing DR.(97). 
Furthermore, patients with DR and anemia had a five fold risk or more of developing 
severe retinopathy than patients with higher hemoglobin.(96) 
Obesity- 
 A number of western studies have shown a relationship with body mass index 
(BMI), sugar control and blood pressure control. (98)(99)(100). In contrast, in Indian 
studies, type 2 diabetics and DR seemed to have a lower BMI. Possibly the difference 
in ethnicity is involved in this difference(73).   
 Ocular factors- 
 There are a number of ocular pathologies which seem to have a protective effect 
on the development of DR.  
• Posterior vitreous detachment may prevent PDR because an intact posterior vitreous 
is needed for retinal new vessels. (101) Therefore a good examination of the 
vitreous is invaluable for predicting the development of DR. 
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• High myopia with chorioretinal atrophy or extensive chorioretinopathy act like 
photocoagulation and reduce the metabolic needs of the retina, thereby protecting 
against development of DR. (102) 
• Cataract surgery, on the other hand, increases the chances of the development and 
progression of DR. (103). As demonstrated by the Palakkad Eye Disease Survey, 
cataract surgery was one of the main causes for decreased vision in diabetic 
patients. (72).  
Other factors 
• Recent reports have demonstrated a link with DR and atherosclerosis, suggesting a 
common pathogenesis between the macro and microvascular complications of 
diabetes. (104). As reported by the CURES study, intima-media thickness and 
artery wall stiffening were significantly associated with DR. (105)  
• There seems to be a role for oxidative stress. Hypoglutathionaemia, along with 
oxidative stress cause altered metabolism which has been postulated to be a 
mechanism for microangiopathy asswociated with DR. (106)(107). 
• As mentioned earlier, there is a role for genetic susceptibility in the development of 
DR. That is most likely why some patients develop DR even after good control 
whereas other patients do not inspite of very poor control. (108)(109). A number of 
studies have shown a clustering of DR among siblings. 
Staging of DR- 
 There are a number of systems of classification of the severity of DR. there is 
considerable overlap between the different systems. All the systems are based on the 
two basic pathologies causing vision loss in DR- retinopathy and maculopathy. The 
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main differences between the systems are related mainly to terminology assigned for 
various levels of severity.  
Classification based on clinical findings alone- 
 Two of the classification systems will be discussed here. 
 The Airlie House system is the gold standard for staging of DR. However, it is a 
very rigorous system and is therefore probably best reserved for research studies. It is 
based on assessment of seven 30 degree stereoscopic photographs of the retina (the 
seven standard fields) and comparing each of the images with standard 
photographs.(110) A score is then given to each eye ranging from 10 (no retinopathy) 
to 85 (proliferative retinopathy). The grades for both eyes are then compared.  
• Field 1- centered on the macula. 
• Field 2- centered on the optic disc. 
• Fields 3 to 8- two above, two below and one nasal to the disc surrounding the fields 
1 and 2 
The findings graded in fields 2 to 8 are haemorrages, microaneurysms, hard 
exudates, cotton wool spots, venous abnormalities (caliber abnormalities, sheathing, 
perivenous exudates), arteriolar abnormalities, intraretinal microvascular abnormalities 
(IRMA) and neovascularisation.  
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Table 7. Modified airlie house grading of diabetic retinopathy (111) - 
Retinopathy  
level 
Retinopathy  
severity Retinopathy definition 
10 No retinopathy Diabetic retinopathy absent 
20 Very mild 
NPDR 
Microaneurysms only 
35 Mild NPDR Hard exudates, cotton-wool spots, and/or mild retinal 
hemorrhages 
43 Moderate 
NPDR 
43A:retinal hemorrhages moderate (>photograph 1A) 
in 4 quadrant or severe (≥ photograph 2A) in 1 quadrant 
43B:mild IRMA (<photograph 8A) in 1 to 3 quadrants 
47 Moderate 
NPDR 
47A:both level 43 characteristics 
47B:mild IRMA in 4 quadrants 
47C:severe retinal hemorrhage in two to three 
quadrants 
47D:venous beading in one quadrant" 
53A-D Severe NPDR 53A:≥2 level 47 characteristics 
53B:severe retinal hemorrhages in 4 
53C:moderate to severe IRMA (≥ photograph 8A) in at 
least 1 quadrant 
53D:venous beading in at least 2 quadrants" 
53E Very severe 
NPDR 
≥2 level 53A-D characteristics 
61 Mild PDR NVE <0.5 disk area in 1 or more quadrants 
65 Moderate PDR 65A:NVE≥0.5 disk area in 1 or more quadrants 
65B:NVD<photograph 10A (0.25-0.33 disk area) 
71 and 75 High-risk PDR NVD ≥ photograph 10A, or NVD < photograph 10A or 
NVE ≥ 0.5 disk area plus VH or PRH, or VH or PRH 
obscuring ≥ 1 disk area 
81 and 85 Advanced PDR Fundus partially obscured by VH and either new 
vessels ungradable or retina detached at the center of 
the macula 
 
NPDR: Non proliferative diabetic retinopathy, PDR: Proliferative diabetic retinopathy, IRMA: 
Intraretinal microvascular abnormalities, NVE: New vessels elsewhere, NVD: New vessels on or within 
1 DP of the optic disk, PRH: Pre-retinal hemorrhage, VH:Vitreous hemorrhage. 
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  The ETDRS in addition, introduced the term clinically significant macular 
edema (CSME)(112). This was defined by three criteria(113)- 
• Thickening of the retina at/or within 500 µm of the center of the macular 
• Hard exudates within 500µm of the macular center along with adjacent retinal 
thickening. 
• An area of retinal thickening 1 disc area, any part of which is within 1 disc 
diameter of the macular center. 
In addition macular edema can be classified as focal and diffuse. (114). However, 
these terms do not have any strong treatment benefit.       
 In order to simplify the Airlie House classification, the International Clinical 
Disease Severity Scale for DR was introduced. This system is simple to use and easy to 
remember. There are five stages 
o Stage 1- No apparent retinopathy 
o Stage 2- mild non-proliferative diabetic retinopathy (mild NPDR):  upto a few 
microaneurysms 
o Stage 3- Moderate NPDR: presence of microaneurysms, intraretinal heamorrages or 
venous beading which do not reach the severity of sever NPDR (standard 
photographs 2A, 6A and 8A) 
o Stage 4- Severe NPDR: 4:2:1 rule, any one of the following  
• heamorrages (of at least the magnitude of photograph 2A) in all 4 quadrants 
• venous beading (at least of magnitude photograph 6A)  in 2 quadrants 
• IRMA ( at least of magnitude photograph 8A) in even one quadrant 
o Stage 5- Proliferative diabetic retinopathy (PDR): neovascularisation of the retina, 
disc, iris, angle, vitreous hemorrhage or tractional retinal detachment.  
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 Some include a stage of very severe NPDR, this falls in between the stages of 
severe NPDR and PDR. 
 Macular edema is either present or absent. If it is present, it can be further 
graded as mild, moderate or severe as regards the distance between the thickening and 
the macular center. (115) 
Classification based on fundus fluorescein angiography (FFA)- 
 The EDTRS proposed a system where there were stereoscopic FFA pictures of 
two 30 degree fields extending along the horizontal meridian from 25 degree nasal to 
the disc to 20 degree temporal to the macula. The pictures were assessed for early mid-
phase capillary drop out, dilatation, arteriolar pathologies and also the size of the foveal 
avascular zone. (116). But this system is complicated and best suited for research. 
Classification of DR based on Optical coherence tomography (OCT)-   
 This non-invasive, non-contact investigative modality is very useful for 
assessment of diabetic macular edema. With the rising importance of anti-VEGF 
therapy for diabetic macular edema, OCT is fast becoming an essential tool for the 
treatment of DR. (117)Several OCT morphological patterns are described for macular 
edema. These include diffuse retinal thickening, cystoids edema, exudative retinal 
detachment, tractional retinal detachment, posterior vitreous traction. (118). 
Unfortunately, there is no consensus till date on a grading system of macular edema 
based on OCT findings alone. (119)  
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Pathogenesis of DR- 
 It would not be an exaggeration to say that the pathogenesis of DR is extremely 
complex. There are a number of vascular, inflammatory and neuronal mechanisms 
involved. (120). Changes in retinal microvasculature are key to understanding the 
disease process. (121).   
 The disease can be simply understood as occurring in two phases. In the first 
phase, there is a compromise of retinal microvasculature which results in the retinal 
capillaries degenerating. This then leads on to an angiogenic over-compensation. The 
early alterations in the retinal microvasculature are a disruption of blood flow, a 
thickened basement membrane, loss of mural cells and formation of abnormal 
capillaries. Due to endothelial cell destruction and capillary loss there is a hypoxia of 
the inner retina. Simultaneously a number of growth factors and inflammatory 
substances-most of them being angiogenic- are secreted leading to the generation of 
abnormal preretinal vasculature. (122)  
The important players of DR pathogenesis- 
 That inflammation and angiogenesis play a major role in DR is widely accepted. 
(123) Of course, the exact underlying mechanism and interactions have not yet been 
clearly elucidated. By studying aqueous and vitreous samples, fibrovascular tissue from 
retinae of eyes affected by DR and vitreous heamorrage, the following mediators 
appear to have key roles in the pathogenesis of DR.  
 
 
 
32 
 
Table 8. Inflammatory mediators of DR 
Vitreous mediators  Function 
 
 
 
 
 
 
 
Cytokines  
IL-6  Regulating immune reponses 
 Increasing vascular permeability 
 Angiogenesis 
 Regulating expression of metalloproteinases 
IL-8  Chemoattractant 
 Angiogenesis  
IL-1β  Angiogenesis 
 Synthesizing collagen 
TNF-α  Antiangiogenic activity 
 Leukocyte adhesion 
 oxidation 
HMGB1  Stabilizing the formation of nucleosomes and 
gene transcription 
 Attenuating retinal injury after ischemia- 
reperfusion 
 Mediating the secretion of survival factors 
 
 
Transcription 
factors 
NF-κB  Regulating immune response, cell 
proliferation and apoptosis 
 Synthesizing cytokines, chemokines and 
proinflammatory molecules 
HIF-1  Regulating cellular responses under acute and 
chronic hypoxia 
 Regulating VEGF expression 
 
 
 
 
 
Chemokines  
 
 
MCP-1  Recruiting and activating macrophages 
 Fibrosis and angiogenesis 
IP-10 Inhibiting angiogenesis 
MIG Angiostatic activity 
SDF-1  Stimulating and mobilizing cells of tissue 
repair, promoting migration, proliferation and 
differentiation of endothelial cells 
 Promoting repair after ischeamic injury 
Angiogenesis  
Fractalkine  Angiogenesis 
MIF Recruiting and enhancing macrophages 
adherence, motility and phagocytosis 
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Growth factors 
 
 
 
 
 
 
 
 
 
 
VEGF  Increasing vascular permeability 
 Angiogenesis 
 Endothelilal cell migration and survival 
 Expression of ICAM and VCAM-1 
PGF  Potentiating the action of VEGF 
 Stimulating endothelial cell proliferation, 
migration and angiogenesis 
Tenascin –C  Modulating cell growth and adhesion 
 Sprouting of endothelial cells 
IGF 1  Regulating the proliferation and 
differentiation of different cell types 
 Stimulating the production of VEGF    
bFGR  Survival/maturation of neurons and glial cells 
 Angiogenesis  
HGF  Modulating the motility, growth and 
morphogenesis of various cell types 
 Angiogenesis  
NGF Stimulating Muller cells to produce bFGF, 
which then stimulates endothelial cell 
proliferation and secretion of VEGF 
CTGF Stimulating proliferation, angiogenesis, 
migration, ECM production, cell attachment, 
cell survival and apoptosis 
Stem cell 
factor 
Survival and differentiation of heamatopoetic 
stem cells  
 
Capillary tube formation of endothelial cells 
 
EPO Anti-oxidant, anti-inflammatory, 
proangiogenic, neuroprotective and anti-
apoptotic 
Adiponectin Anti-inflammatory and antiatherosclerotic  
Adhesion 
molecules 
ICAM-1, 
VCAM-1, 
E-selectin 
Leukocyte recruitment 
Soluble 
vascular 
adhesion 
protein 
Leukocyte recruitment  
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Proposed interaction of the key implicated mediators in the the pathogenesis of DR-  
 One of the earliest changes seen in the development of DR seems to be a 
decrease in retinal blood supply due to the constriction of major arteries and arterioles. 
(122)(124). This reduction in blood supply, results in the initiation of a cellular cascade. 
Among the initial inflammatory mediators, the PKC isoforms appear prominent. The 
PKCII especially seems to be secreted in DR. (125). This leads to increased vascular 
permeability, destruction of the blood-retinal barrier and a loss in endothelial tight 
junctions.(122)(126). The retinal arteriolar smooth muscle cells (BK channels) 
dysfunction plays a key role in retinal hyperperfusion by adding to the vascular 
constriction.(127)(128) Additionally there is a loss of retinal pericytes. All the above 
eventually represent an end point of endothelial cell degeneration, destabilization and 
faulty perfusion of the retinal tissue.(122)(129)(130). The loss of pericytes seems to an 
increase in activity of OKC and a inhibition of platelet derived growth factor 
(PDGF).(131). Thus develops a chronic inflammation ultimately leading to capillary 
obstruction. (132). 
 This obstruction effectively results in retinal perfusion deficiencies, faulty 
oxygenation of retinal tissues and hypoxia. The chronic hypoxia results in secretion of a 
number of inflammatory mediators. The oxygen deficit with the added effect of the pro-
inflammatory cytokines (TNF-α, IL-6 and -1β) leads to the enhanced expression of 
VEGF – now one of the emerging key players in the pathogenesis of neovascularisation 
of DR. 
 As a result of the above alterations, the retinal capillary basement membrane 
becomes thickened, with oversecretion of fibronectin, collagen IV and laminin, causing 
the formation of vessels with markedly abnormal integrity. This constitutes the stage of 
neovascularisation and if left untreated can progress on to advanced DR causing a loss 
of vision to the eye.           
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Figure 3. Outline of the pathogenesis of DR (121) 
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The role of VEGF in the pathogenesis of DR 
What is VEGF? 
 VEGF is a dimeric 40kDa glycoprotein. It is a powerful stimulator of 
proliferation, migration and tube generation needed for the growth of new blood 
vessels. It is thus essential for angiogenesis during development and a deletion of even 
one allele is lethal for the embryo.(133)(134)(135). There are seven members in the 
VEGF family: VEGF- A (commonly referred to as VEGF), VEGF-B, VEGF- C, 
VEGF- D, VEGF-E, VEGF-F and PIGF (placental growth factor). In addition to the 
above seven, splicing of VGF results in a variety of VEGF variants: such as VEGF121, 
VEGF189, VEGF206. The degree of solubility of these variants depends primarily on 
their heparin binding capacity. Thus, variants which bind tightly to heparin remain 
mainly in the extracellular matrix (eg. VEGF206 and VEGF189),  whereas some have no 
heparin binding specificity at all (VGF121).     
VEGF receptors- 
 Of the VEGF receptors (VEGFR) VEGFR-1 and VEGFR-2 are the ones mainly 
concerned with angiogenesis (136).  The VEGFR are organized into a seven-
immunoglobulin-like folded extracellular domain, leading onto a juxtamembrane part 
which further continues to a split tyrosine-kinase domain. This latter part has a 70-
amino-acid insert and a C-terminal tail.  
 Dimerization is required to activate the VEGFR. Dimerization of the VEGFR 
causes activation of kinase activity and autophosphorylation. Tyr1214 is necessary for 
the autophophorylation of the receptor and thus its signaling protein activity.  
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Figure 4. The various isoforms of VEGF and basic receptor structure (137) 
 
Regulation of VEGF production- 
 Hypoxia is a very strong stimulus for VEGF expression. According to Dor et al, 
hypoxia causes VEGF expression by a number of mechanisms. (138). These are namely 
increase in transcription, mRNA stabilization, protein translation, increased oxygen 
regulated protein 150, which is necessary for intracellular transport of proteins. 
(139)(140)(141)(142). 
 Hypoxia inducible factor-1 (HIF-1) has a role in the increased transcription of 
VEGF. HIF-1 has two subunits, and inducible component HIF1-α and an innately 
manufactured part HIF1-β.(143) Under normal conditions, HIF1- α, is inactivated and 
degraded. But in hypoxia this process in inhibited and the degradation of HIF1-α is 
halted.(144) As a result of this, HIF1-α combines with HIF1-β, ultimately resulting in 
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the generation of a hypoxia responsive element (HRE). (145) Recently, HIF-2α and 
HIF-3α have been isolated. HIF-2α is similar to HIF-1β. However, additional studies 
are needed to clearly elucidate the importance of these molecules.  
 Evidence for the increase in VEGF mRNA comes mainly from in vitro studies. 
VEGF mRNA are increasingly delicate in normal conditions, during periods of 
hypoxia, it is protected from degradation by HuR, increasing its half life from less than 
an hour (in normal conditions) to about 2 to 3 hours. (146) 
 As mentioned earlier, there is an increase in the production of oxygen regulated 
protein 150 (ORP150) in hypoxic conditions. This OPR150 seems to act as a molecular 
chaperone to help VEGF protein transportation and secretion. Therefore, VEGF 
secretion is not only regulated by hypoxia. (142) 
 In addition, insulin-like growth factor 1 (IGF-1) also has a role in retinal 
neovascularisation; by affecting VEGF. (147)There are a number of studies 
demonstrating the importance of IGF-1 in normal angiogenesis. (148)For example, 
preterm babies with reduced IGF-1 have more retinal disease. Similarly mice without 
the IGF-1 gene have problems in retinal vasculature. (149)   
VEGF and VEGFR in retinal diseases- 
 VEGF has been implicated in a number of retinal diseases. These include DR, 
age-related macular degeneration, retinopathy of prematurity, sickle cell retinopathy, 
vascular occlusions and also in neovascular glaucoma.(150)  
 There seem to be 5 cells of the retina capable of secreting VEGF. These are 
the(151)(152)(153) 
• Retinal pigment epithelial cells (RPE) 
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• Astrocytes 
• Muller cells 
• Vascular endothelium 
• Ganglion cells 
 However in conditions of hypoxia, studies show that Muller cells and astrocytes 
produce the most amounts of VEGF. (154)The exact role of the splice variants is still 
unclear. However it is seen that VEGF 120/120 mice retinas had severe vascular 
pathology, VEGF188/188 had normal retinal veins but no arteries.  
 In human adults, expression of VEGF is restricted to the inner nuclear layer (ei. 
the Muller cells and the amacrine cells), the ganglion cells and the retinal vessels.(155) 
During neural development of the retina, VEGFR-2 can also be manufactured by the 
neural progenitor cells.(156) Interestingly, VEGFR-1 and 2 has not been found to be 
expressed by retinal smooth muscles.  
VEGF and DR- 
 That there is an association between VEGF and the pathogenesis of DR is now 
an undisputable fact-  especially, considering the number of studies showing a positive 
correlation between increased intraocular levels of VEGF and PDR. Animal studies by 
Gilbert et al have demonstrated retinal changes similar to background diabetic 
retinopathy by increasing VEGF levels and increasing VGEFR2 expression.(157)(158) 
Blocking VEGF activity has been shown to prevent the development of diabetes-
induced vascular permeability, thereby underlining the importance of VEGF in the 
pathology of diabetic macular edema (DME) by increasing vascular 
permeability.(159)(160)(161)  
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VEGF gene expression in DR- 
VEGF expression-  
 The regulation of the VEGF gene is very tightly controlled and over-expression 
has been linked to a number of diseases; including DR. The extent of activity of VEGF 
is positively linked to the expression of its gene. In diabetes, many factors act towards 
the over-expression of VEGF, such as tissue hypoxia, growth factors, inflammatory 
cytokines and reactive oxygen radicals. In the next few paragraphs we will go through 
the regulatory mechanisms for VEGF gene expression and how they are important in 
diabetes 
Transcriptional regulation of VEGF gene expression 
 Hypoxia is a most important factor and the most studied one for VEGF 
regulation. Studying diabetic mice, de Gooyer et al reported a decrease in retinal 
capillary density along with periods of hypoxia.(162) As already stated, the HIF-1 
transcription factor is involved in this transcriptional increase in VEGF. However, these 
increases in VEGF levels are detected very early on, before any capillary drop out has 
been detected. Therefore the exact mechanism behind the hypoxia induced over-
expression of VEGF is still not clearly known.   
 Apart from hypoxia, TGF-β, TNF-α. IGF-1, advanced glycation products and 
oxidative stresses are involved in the upregulation of VEGF expression in diabetes. 
(163)(164)(165)(166). The exact mechanisms by which these factors achieve such an 
end point is not clear and seems to be complicated, to say the least. 
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The post-transcriptional regulation of VEGF expression- 
 Though the VEGF post-transcriptional events (in normal and abnormal 
situations) is known, how elevated sugars alter the post-transcriptional events is not so 
well known. There seems to be a change in mRNA stabilization and activation of 
multiple internal ribosomal entry sites(IRES) . IRES is involved in the production 
variant VEGF isoforms splices. How this plays a role in DR will be explained in the 
next section. 
VEGF splice variants-  
 The different splice variants of VEGF play a number of parts in retinopathy. 
VEGF165 seems to be a powerful agent of retinal inflammation and also neuronal 
survival. (167) (168)In contrast VEGF121 is involved only in neuronal activity and not 
in inflammation. In vitreous from eyes with DR, there was found to be  decreased 
levels of the negative splice variant VEGF165b, pointing to a molecular switch 
between VEGF165 and VEGF165b. (169) 
VEGF autocrine activity in the endothelial cells- 
 Though VEGF is mainly a paracrine factor, in hypoxia, it appears to have 
autocrine abilities- stimulating its own production form endothelium of the 
microvasculature.(170). The exact importance of this autocrine secretion is not known, 
but high glucose and reactive oxygen species can induce VEGF expression for retinal 
endothelial cells in experimental conditions. Possibly these inhibit proteins that are 
normally inhibitory to the production of VEGF.   
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Figure 5. VEGF gene upregulation leads to increase in VEGF expression and 
activity(137) 
 
VEGF activity regulation in DR 
VEGF and Vascular inflammation-  
 A number of facts have been experimentally demonstrated to shown that VEGF 
has a role in inflammation and DR. Endothelial cells treated with VEGF show 
increased expression of ICAM-1 and MCP-1. (171)(172)(173)The retinas of diabetic 
animals show increases in VEGF expression correlating with increased ICAM-1 
immunoreactivity and leukostasis. Specifically VEGF165, as mentioned earlier has a 
role in this and intravitreal injecton has been shown to induce the expression of ICAM-
1 in retinal vasculature.  
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VEGF and Vascular permeability- 
 There is a breakdown in the blood-retinal barrier of the vascular endothelium in 
diabetes. This breakdown correlates with increased VEGF in ocular 
specimens.(174)(175)(176) There are a number of pathways implicated in this increase 
in vascular permeability.  
 As demonstrated by Roberts et al, topical or intradermal application of VEGF is 
followed by an increase in capillary permeability, formation of fenestrations and a 
trans-cellular permeability pathway.(177). Further studies have shown that VEGF 
treatment results in an initial rapid increase in transcellular permeability lasting about 
an hour. This is facilitated by a transcytotic transport of caveolin-coated vescicles and 
was accompanied by nuclear translocation of VEGFR2. This was then followed by a 
more sustained increase in vascular permeability which involved the translocation of β-
catenin. (178) 
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VEGF-induced increase in vascular permeability probably occurs as a result of 
endothelial cell-to-cell attachment disruption involving interactions between MMP-9, 
plasmin and uPAR on the cell surface. (179)(180)(181)This proteolysis alters 
attachments between cells, thus generating leaky vessels, allowing endothelial cell 
penetration of basement membrane. After this the cells can migrate and proliferate 
unchecked, setting the scene for retinal neovascularisation. This schema of events has 
been supported by a number of experimental studies.    
 
Figure 6. Experimental model showing VEGF induced increase in caveoli 
(137) 
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Retinal angiogenesis- 
 Vasculogenesis is a term used to describe a phenomenon where marrow-derived 
endothelial progenitor cells (EPC) in circulation are recruited and incorporated into 
new vessels. VEGF, apart from it’s well know role in angiogenesis, has a part to play in 
altering vasculogenesis. (182) (183)(184) EPC’s from diabetic patients have impaired 
proliferation, adhesion and incorporation into the blood vessels.(185) Studies in an 
experimental environment of retinal ischemia have demonstrated the participation of 
marrow derived hematopoetic stem cells in neovascularistion.(186)  Furthermore, 
normal EPCs can in fact repair injured retina. EPCs from diabetics have been 
demonstrated to be unable to perform this function effectively. (187) 
 
Figure 7. Postulated interactions for the increased permeability of DR (137) 
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VEGF and cell longevity- 
 VEGF has a definite contribution to endothelial cell survival. Ironically, in the 
diabetic, though levels of VEGF and VEGFR2 are increased, the endothelial cell 
survival is reduced. (188)(189) This fact is well-established by the presence of acellular 
capillary capillary network and increased apoptosis of the endothelial cell. These 
seemingly contradictory discoveries suggest some additional alteration to the VEGF 
mediated survival of endothelial cells in the diabetic environment. 
Analysis of VEGF 
Ocular fluid-  
 In the original study by Aiello et al, VEGF concentrations in ocular samples 
were measured by a radioimmunoassay using two monoclonal antibodies bound to 
different epitopes on VEGF 165 and other larger isoforms. They performed the assays 
using 96-well immunoplates. Each of these plates were coated with 100µl of anti-
VEGF monoclonal antibody. The plates were then washed thrice, blocked for one hour 
at 25 degree Celsius with 0.5% bovine serum albumin and 0.03 percent Tween 80 in 
phosphate-buffered saline. They are then washed with 0.03 Tween 80 before adding 
diluted sample of ocular fluid or standard solution of VEGF165. 
 The plates were then kept for a 2 hour incubation at 25 degree. After discarding 
the supernatant fluid, the wells were washed and 100 microlitres of 125I-labeled anti-
VEGF monoclonal antibody was added. The plates again underwent a two hour 
incubation. At 25 degree, after discarding the supernatant, and washing, the wells were 
subjected to counting by gamma scintigraphy. The VEGF concentrations were 
quantified from a standard VEGF curve.  
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Recent studies now use enzyme linked immunosorbent assay (ELISA) kits to measure 
VEGF concentrations. 
Blood- serum or plasma- 
For the analysis of VEGF levels in serum and plasma samples, ELSIA kits are 
commonly used.  
In our study we have used the Neogen Corporation’s Human VEGF ELISA Test 
kit. This is designed for the quantitative determination of human VEGF in serum, 
plasma and cell cultures. 
Briefly, the procedure involves a solid phase sandwich ELSIA technique. A 
monoclonal antibody specific for human VEGF is coated onto 96 wells. Samples are 
added to the wells and any human VEGF present binds to the antibody-capture 
antibody. 
The wells are then washed and biotinylated polyclonal anti-human VEGF 
antibody (detection antibody) is added. After washing again, avidin-horseradich 
peroxidase (avidin-HRP) is added, thereby resulting in an antibody-antigen-antibody 
sandwich. The wells are washed again and substrate solution added. This is to produce 
a blue color in proportion to the amount of human VEGF in the test (initial) sample. 
This kit has a sensitivity of 15pg/mL and a specificity of 100% for human 
VEGF. 
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Study of VEGF levels in DR 
Ocular fluid and VEGF in DR 
 The search for a “hypothetical angiogenic substance”-the culprit for the 
devastating complications of neovascularisation seen in DR ended in 1994 when Aiello 
et al in their paper analysed VEGF levels from the ocular fluid of patients with 
pathological neovascularisation. They reported VEGF detection in 69 of the 136 
samples from patients with DR, 29 of 38 samples from patients with iris 
neovascularisation, and 3 of 4 sample of patients with vein occlusions as compared to 2 
out of 31 patients with no vascularisation.(4). 
 
 
Figure 8. VEGF levels from ocular fluids Aiello et al (4) 
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 As can be seen from the above graph, VEGF was significantly elevated in 
patients with active neovascularisation.  
 Subsequently, there have been numerous reports of increased VEGF 
concentrations in vitreous, aqueous, neovascular membranes and vitreous hemorrhage 
of patients with DR.   
Serum and plasma levels of VEGF in DR- 
 The literature on serum levels of VEGF and DR can at best, be described as, 
contradictory.  
 There is one study by Hellgren et al where they report an increase in levels of 
circulating VEGF in preterm infants who later went onto develop severe retinopathy of 
prematurity. (190).  
 Meleth et al in a study on serum inflammatory markers in DR report a 
significant elevation in the chemokines RANTES and SDF-1apha. There is no clear 
data regarding VEGF levels in this study.(191) 
 A study by Semeraro et all where they compared systemic and intraocular 
concentrations of VEGF and erythropoietin (EPO) between 33 type 2 diabetics and 
undergoing vitrectomy for PDR patients (cases) with 20 patients undergoing vitrectomy 
for macular holes or puckers (controls).(192) They reported no significant difference in 
serum levels of EPO between the two groups. VEGF levels in serum were 
paradoxically lower in diabetics. The authors conclude that there must be other 
confounders affecting the serum concentrations of these markers.  This has also been 
suggested by GUo et al where they report a positive association between serum EVGF, 
ferritin and the development of retinopathy. (193)   
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 Another study by Fan et al on 1040 Chinese people with type 2 diabetes 
reported higher serum VEGF levels in patients with retinopathy than those without. 
(194) Koleva-Gerogieva et al also report similar findings in their study on serum 
inflammatory cytokines and DR. (195) Li et al also state the importance of serum 
cytokines and VEGF in the diagnosis of PDR in their study on 30 patients. (196) 
 However, Praidou et al report no such correlation between serum levels of 
VEGF and DR.(197) 
 Soiberman, Davidovic et al, on the other hand, in their report on serum levels of 
VEGF following intravitreal ani-VEGF injections describe a decrease in serum VEGF 
level following the injections. (198) (199). 
 The studies are many and a variety of associations between serum VEGF and 
DR have been proposed and disputed. There is one study by Cavusoqlu et al on 65 
patients studying the serum levels of VEGF at different stages of DR. However they 
state that the levels were different in the groups. They report a correlation between 
serum VEGF and HbA1c levels.(200) To the best of our knowledge there is no report 
thus far on serum VEGF, grading of diabetic retinopathy in such a large number.  
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Materials and Methods  
Study population- 
Outpatients presenting to the Ophthalmology department of   PSG Hospitals 
with clinical diagnosis of Type 2 diabetes mellitus for routine diabetic retinopathy 
screening. 
Inclusion criteria- 
1. Type 2 Diabetics with retinopathy 
 2. Type 2 diabetics without retinopathy  
Exclusion criteria- 
1. Type 1 Diabetes Mellitus 
2. Other retinal diseases  
3. Terminally ill patients 
4. Patients who have received prior anti-VEGF therapy.  
Sample size- 
Due to money and time constraint a convenient sample of 75 patients with type 
2 diabetes and presenting to the outpatient department for routine diabetic retinopathy 
screening were chosen. This sample size was chosen after reviewing the existing 
statistics collected from the department register which showed that on an average 30-32 
patients attended our OPD over a period 3 months for diabetic eye screening.  
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Tool used- 
• ETDRS classification of diabetic retinopathy based on 500 7 field fundus 
photography 
• Human VEGF ELISA Kit 
Study design: 
Descriptive analytical study 
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Methodology-  
 
 
 
 
 
          
                                                               
         
 
          
                                             
                                                                          
                                                           
                                                                         
    
                                                                          
                                                                       
                                               
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Type 2 Diabetic patients attending PSGIMSR  
Ophthalmology OPD  during the 1 Year period 
Detailed examination with slit lamp, 90 D and 
indirect ophthalmoscopy 
75 patients with type 2 DM selected 
15 with no DR 
15 with mild NPDR 
15 with moderate NPDR 
15 with severe DR 
15 with PDR 
Informed consent 
50 degree field fundus photograph, grading of 
retinopathy with ETDRS classification 
5 ml of blood for estimation of vascular endothelial 
growth factor with ELISA kit after separation of serum 
by centrifugation 
Result analysis 
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ELISA- 
The concentration of serum VEGF levels in the sample will be quantitatively 
measured by using ELISA  kit for human VEGF(Neogen U.S.A  Human VEGF Product 
#452610) 
Statistical analysis- 
Analytical software used was SPSS version 19. 
Count data were analyzed using the Chi-square test. Continuous variables were 
analyzed using the Students’s t test, Independent one sample t test, and Analysis of 
variance (ANOVA).  
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Results 
Demographic characteristics of the population under study. 
Total number of patients- 75 
No NPDR=15 
Mild NPDR=15 
Moderate NPDR=15 
Severe NPDR=15 
PDR=15 
 
Average 
in study 
population 
No DR Mild NPDR 
Moderate 
NPDR 
Severe 
NPDR PDR 
P 
value 
Age 58.16 
years 
(SD=8.6) 
58.67 
years 
(SD=10.4) 
58.53 
years 
(SD=8.4) 
59.07 
years 
(SD=7.3) 
56.00 
years 
(SD=7.8) 
58.53 
years 
(SD=9.1) 
0.880 
Sex 
ratio 
(M:F) 
2.75:1 1.5:1 2.7:1 2.7:1 6.5:1 2.7:1  
P value less than 0.05 taken as significant. 
 
 
 P value= 0.88 
Primary outcome measures
VEGF levels 
 VEGF and the normal population
Overall mean VEGF levels for the study population of 75 diabetic patients was 
577.01 pg/ml (SD= 291.13)
On reviewing the literature, the 
707 pg/ml. Assuming that the range of VEGF for the normal population follows a 
typical bell-shaped distribution, we used the independent one sample t
our mean VEGF result with the normal range.  Ou
significantly elevated when compared with the normal population. (p value =0.00001.)
Comparing specifically, the VEGF in patients with no DR and the normal 
population was also significantly elevated. 
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normal limits for VEGF were found to be 72
r VEGF levels were found to be very 
(p value= 0.0076) 
mild NPDR mod NPDR severe NPDR
Age vs the severity of DR
 
-
-test to compare 
 
PDR
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VEGF levels and the grade of DR 
The lowest value of VEGF was seen in the no DR group (34 pg/ml). The 
highest value was seen in the mild DR group (1296 pg/ml).  
Overall, there was no statistical significance in the variation of VEGF and the 
grade of DR. (p value=0.544). 
 
 
P value=0.544  
(p value less than 0.05 taken as significant) 
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Mean VEGF 
(pg/ml) Standard deviation 
No DR 620.73 293.50 
Mild NPDR 666.15 314.68 
Moderate NPDR 545.06 264.13 
Severe NPDR 556.06 293.53 
PDR 496.48 296.43 
 Secondary outcome measures
Duration of diabetes  
The average duration of diabetes in the study population was 7.2 years.
The subpopulation without any diabetic retinopathy had the minimum duration 
of 6.53 years. The population with mild NPDR had the maximum duration of 
years. There was no statistically significant difference in the duration of diabetes and 
the grade of diabetes. (p value=0.137)
 
 
 
 
 
P value=0.137  
(p value less than 0.05 taken as significant)
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5 10
mean duration of diabetes in years
Duration of diabetes 
in years 
Standard 
deviation
6.53 6.73
 12.80 9.38
 9.33 5.62
 11.93 6.66
10.27 6.23
 
12.80 
 
15
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Heamoglobin levels  
The average haemoglobin level in the study population was 11.53 gm/dl 
(SD=2.00).  
There was no significant difference in the haemoglobin levels and the severity 
of diabetes. (p value=0.791) 
 
Mean haemoglobin 
in gm/dl 
Standard 
deviation 
No DR 12.11 1.86 
Mild NPDR 11.31 2.32 
Moderate NPDR 11.57 2.61 
Severe NPDR 11.36 1.69 
PDR 11.29 1.47 
 
 
P value=0.791   
(p value less than 0.05 taken as significant) 
 
Urea levels- 
The mean urea levels in mg/dl of the whole population was 35.47 mg/dl 
(SD=25.80).  
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 There was no significant difference in the levels of urea and the severity of 
diabetes (p value=0.138).
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P value=0.138 
(p value less than 0.05 taken as significant)
 
Serum creatinine levels 
The mean creatinine levels for the 
The minimum value was seen in the patients with no DR (0.91 mg/dL). The 
highest values were seen in the group with PDR (2.26 mg/dL). However any intergroup 
variation of creatinine was not statistically significant. (p v
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Mean urea 
levels in mg/dl 
Standard 
deviation 
24.73 19.36 
 33.90 17.95 
 35.45 28.97 
 34.10 29.43 
49.17 28.07 
 
population was 1.42mg/dL  (SD=1.55).
alue= 0.11)
mild NPDR mod NPDR severe 
NPDR
PDR
 
 
 
  
No DR 
Mild NPDR
Moderate NPDR
Severe NPDR
PDR 
 
P value= 0.11 (p value less than 0.05 taken as significant)
Random blood sugar levels
The mean random blood sugar levels for the whole population were 228.95 
mg/dL (SD=74.499). 
The normal random blood sugars were taken to be 70
statistical analysis, the raise in the mean random blood sugar was found to be 
significant.  
However, there was no statistically significant change in the random blood 
sugar levels and the severity of diabetes (p value=0.430). 
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Mean creatinine 
values (mg/dL) 
Standard 
deviation
0.91 0.76 
 1.32 1.03 
 1.25 1.09 
 1.28 1.16 
2.36 2.69 
 
 
-
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NPDR
PDR
 
 
140 mg/dL. After 
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Mean random blood sugar 
mg/dL 
Standard 
deviation 
No DR 222.07 73.222 
Mild NPDR 249.07 86.633 
Moderate NPDR 216.00 71.762 
Severe NPDR 249.00 85.675 
PDR 208.60 49.406 
 
 
P value=0.430 
(p value less than 0.05 taken as significant) 
 
Fasting blood sugar levels 
The mean fasting blood sugar levels for the 75 patients was 165.87 mg/dl 
(SD=59.04). 
However, there was no significant difference in the fasting blood sugar levels 
and the severity of diabetes (p value=0.408) 
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Mean fasting 
sugars mg/dL Standard deviation 
No DR 162.87 55.564 
Mild NPDR 183.00 82.532 
Moderate NPDR 156.67 40.334 
Severe NPDR 179.13 54.536 
PDR 145.67 54.052 
 
 
P value=0.406 
(p value less than 0.05 taken as significant) 
 
HBA1C levels 
The mean HBA1C levels were 9.49% (SD=2.37) 
The lowest HBA1C levels were seen in the group with no DR (8.45%) and the 
highest was seen with the group with severe NPDR (10.46%). However, the difference 
was not statistically different (p value- 0.230) 
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P value=0.230  
(p value less than 0.05 taken as significant)
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no DR mild NPDR mod NPDR severe 
NPDR
PDR
HBA1C vs severity of DR
Mean 
HBA1C (%) Standard deviation
8.45 1.57
9.72 2.06
 9.47 1.65
 10.46 3.45
9.32 1.90
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Discussion 
Diabetic retinopathy is without doubt one of the most significant ocular 
complications of a systemic disease. Unfortunately the numbers of patients with DR is 
on the rise and it is one of the most common causes of blindness in many parts of the 
world, especially of the middle aged population. It has been shown in a countless 
number of studies that the vasculogenic factor –VEGF- plays a prime role in the 
pathogenesis of the DR. That vitreous levels of VEGF are elevated in patients with DR- 
in particular active, advanced stages of DR- is an undisputable fact. However, the 
association of blood VEGF levels and diabetic retinopathy has not been studied quite so 
much, and whatever studies are there report conflicting data.  
The aim of our study was to study serum VEGF levels of diabetic patients with 
and without diabetic retinopathy, and if there was any such association, to discern a 
relationship of serum VEGF levels with the severity of diabetic retinopathy.  
Our study design was a descriptive analytical study of patients with diabetes 
mellitus type 2 presenting to our out patient department for routine diabetic screening. . 
We selected a representative sample size of 75 patients, which included 15 patients 
without any retinopathy, 15 with mild DR, 15 with moderate DR, 15 with severe DR 
and 15 with PDR. After obtaining informed consent from the patient, we drew a 5 ml 
sample of venous blood for the analysis. The sample was subsequently subjected to 
centrifugation and using the human serum VEGF ELISA kit (Neogen U.S.A  Human 
VEGF Product #452610) the VEGF levels in the serum sample were obtained.   
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Demography- 
The average age of the patients in the study population was 58.16 years. This 
result is to be expected as type 2 diabetes mellitus is mainly a disease of the middle 
aged and our study was only on type 2 diabetics. Any patient with type 1 diabetes was 
excluded from the study. 
 Earlier studies done in similar populations from South India report age and 
longer duration of diabetes as risk factors for DR. (201)(202)(73). However, in our 
study, further analysis of the age and the severity of diabetes showed no statistical 
significance. 
Regarding the association with gender, the majority of the patients were male, 
with an overall male to female ratio of 2.75:1. A similar result was reported by Raman 
et al, where they report an increased risk of DR among male patients (Odds ratio=1.41). 
(202). 
Primary outcome measures- 
The serum VEGF level in the 75 patients was taken as our primary outcome. 
The average serum VEGF levels were 577.01 g/ml. On comparing this value with the 
known normal serum VEGF levels, our result was proven to be very significant. This 
result has been reported in a number of other studies as well. (194)(195).  
We then analyzed the elevation between the group with no DR and the normal 
population values. This too was significantly elevated (p value= 0.0076). Therefore, it 
appears that VEGF is elevated in diabetics per se, and not specifically in patients with 
diabetic retinopathy. This can be explained by the fact that VEGF is a systemic factor 
and not confined to the eye. VEGF has been implicated in the pathogenesis of not only 
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diabetic retinopathy, but also in diabetic nephropathy, neuropathy and even diabetic 
macrovascular disease.(203)(204)(205) 
Paradoxically, the group with PDR had the minimum mean value of VEGF. The 
group with mild NPDR had the maximum mean VEGF value. On testing the relation 
between VEGF and the severity of DR, there was no statistical significance detected. 
Similar results have been obtained in a number of other studies. (197)  
Hence, to answer our primary research question, serum VEGF levels are 
elevated in diabetics when compared with the normal population. But there is no 
relationship with the severity of diabetic retinopathy. 
Secondary outcome measures 
Duration of diabetes- 
 In our study, the average duration of diabetes was 7.2 years. 
 There was no statistically significant relationship between the duration of 
diabetes and the severity of diabetes. However, the group with the minimum number of 
years of diabetes was the group with no DR. This is in keeping with the established fact 
that the duration of diabetes is an important risk factor for the development of 
retinopathy.  
Heamoglobin level- 
 The mean heamoglobin level was 11.53gm/dL. Taking the normal range of 
heamoglobin to be 12-15gm/dL, our population appears to be on the aneamic side. In 
addition, the group with PDR had the lowest mean heamoglobin of 11.29; the group 
with the highest heamoglobin was the group with no DR. 
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Though this is not statistically significant, this trend is in keeping with the fact 
that anemia worsens the retinopathy status. Additionally, treating anemia has been 
proven to improve retinopathy and delay its progression. (96). 
Urea and creatinine levels- 
 The average urea level for our population was 35.47 mg/dL. Taking the normal 
range of serum urea to be from 14-40 mg/dL, this value falls into the high normal 
range. 
The mean creatinine levels were 1.42 mg/dL. As the normal range of creatinine 
is 0.66- 1.09 mg/dL, this definitely falls into the high range. 
There was no statistically significant relationship between the creatinine levels 
or urea levels and the severity of diabetes. Even so, the group with PDR had the highest 
urea levels and creatinine levels. Likewise, the group with PDR had the highest urea 
and creatinine levels.   
This is very much in keeping with the fact that both nephropathy and 
retinopathy are microvascular disease and often the presence of one indicates the 
presence of the other. However, there is also a good chance of this renal disease being 
non-diabetic in origin. As highlighted in an earlier study by Prakash  et al, nondiabetic 
renal disease versus diabetic disease was 22.6% vs 3.2% when the duration of diabetes 
was between 5 to 10 years. It is only after 10 years of diabetes that, diabetic renal 
disease jumped ahead to 32.2% vs 6.5% for non diabetic renal disease. (206). As our 
population mean duration of diabetes was 7.2 years, it is likely that the any renal 
impairment is more of a nondiabetic origin.    
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Random blood sugar and fasting blood sugar levels-  
 The average random blood sugar levels for the whole population was 228.95 
mg/dL and the mean fasting blood sugar levels was 165.87 mg/dL. Both these values 
are elevated when compared with normal values. This fact not only highlights the 
chronic hyperglycemia associated with diabetes, but also that most of patients seem to 
have suboptimal sugar control. 
This fact has important long-term prognostic value as it has been proved in 
numerous studies that control of blood sugar and other co-morbidities play a major role 
in the control of diabetic complications.  
There was no statistically significant association between the levels of random 
and fasting blood sugar and the severity of diabetes.  
HBA1C levels- 
 The mean HBA1C level for our study population was 9.49%. The normal upper 
limit is taken to be 6.3%. As the HBA1C level indicates the state of blood sugar control 
for a prior three months, this indicates a very poor control of sugars. This result only 
reinforces the conclusion in the previous section. 
 However, there was no significant relationship between HBA1C levels and the 
severity of DR.  And no general trends were observed. 
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Conclusion  
Serum VEGF levels were found to be significantly elevated in our study 
population when compared with the normal VEGF levels. This elevation of VEGF was 
observed in the entire diabetic population irrespective of whether they had retinopathy 
or not.  
There was no significant relationship between the serum VEGF levels and the 
severity of DR. 
Anemia was associated with severe grades of retinopathy.   
There was an elevation of urea and creatinine levels in the study population; this 
elevation was higher in the more severe grades of DR. 
 Random blood sugar and fasting blood sugar levels were high in the study 
population indicating a state of chronic hyperglycemia and also suboptimal control of 
sugars. 
The trend in HBA1C levels mirrored that of random and fasting blood sugars 
again highlighting a poor control of sugars.    
In conclusion, an elevated serum VEGF level is significantly associated with 
diabetes mellitus and is linked to many of its complications. Though, there is much we 
are yet to discover about VEGF and its exact role in the pathogenesis of diabetic 
retinopathy one thing is certain, in VEGF lies a potential treatment and preventive 
strategy of not only diabetic retinopathy but also of many of the complications of 
diabetes. 
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Limitations  
 Many of the parameters studied showed wide standard deviations. This could be 
because of a small sample size. Possibly due to this same reason many of the outcome 
measures did not show a statistically significant relationship with the severity of DR.  
Therefore, by increasing the sample size it is possible we could have obtained more 
significant results. 
We did not have a population of healthy controls. Hence, we could only 
compare our study population with known normal ranges. Having a group of age and 
sex matched healthy control could have eliminated any confounders which might have 
arisen. 
We did not study other co-morbid conditions such as blood pressure, obesity, 
hypercholesterolemia. All these factors have been proven to affect the complications of 
diabetes and they would have made for useful study. 
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Annexure 1.   
STUDY PROFORMA 
1) AGE    : 
2) SEX    : 
3) DURATION OF DIABETES : 
4) COMORBID CONDITIONS : 
5) LOCAL EXAMINATION OF EYE : 
FINDINGS RIGHT EYE LEFT EYE 
LIDS  
 
 
CONJUNCTIVA  
 
 
CORNEA  
 
 
ANTERIOR 
CHAMBER 
 
 
 
IRIS   
 
 
PUPIL  
 
 
LENS  
 
 
VISION  
 
 
TENSION  
 
 
OCULAR 
MOVEMENTS 
 
 
 
FUNDUS  
 
 
 
6) RESULT OF VEGF LEVEL IN BLOOD (ELISA METHOD): 
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Annexure 2.   
CONSENT FORM 
I have been explained, in a language that I can understand, about the study 
being conducted. I understand that this study is being conducted purely for research 
purposes. All that is required is 5 ml of blood which will be drawn only once. I am 
aware that I have the freedom to choose not to participate and my decision will have no 
bearing on my treatment. 
All my reports and results will be maintained with strict confidentiality.   
 
 
 
 
 
 
Patient signature 
Place 
Date  
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Annexure 3.  RAW DATA 
NO DIABETIC RETINOPATHY 
S.NO NAME AGE SEX OP NO. IP NO. 
VEGF 
LEVEL 
DURATION HB % UREA CREATININE 
HBAIC% 
RBS FBS 
(YEARS) 
 
(mg/dl) (mg/dl) (mg/dl) (mg/dl) 
1 DHANDAPANI . S 55 M O09004308 I14032002 702.175 6 14.4 22 0.87 11.1 297 161 
2 THULSIAMMAL.P 72 F O13035389 I14032947 853.228 7 11.1 16 0.49 7.52 151 175 
3 ABDUL RAHIM.H 82 M O14080159 I14033601 466.2252 1 14.5 13.55 0.6 7.9 182 165 
4 CHELLAMMAL.N 55 F O14081811 I14034441 633.9442 8 11.4 16 0.3 5.93 157 93 
5 PALANISAMY.R 56 M O15001404   705.0335 2 11.6 19 0.57 9.9 291 207 
6 NARAYANASAMY 68 M O10047831 I15001859 341.1629 2 13.3 18.22 0.85 8.24 205 158 
7 ARUNMUGAM.S.L 65 M O150010792 I15004869 1100.048 1 12 17.29 1.04 6.34 230 133 
8 ARUCHAMY 50 M O15025319 I15011508 31.44165 3 11.9 26 0.61 7.8 217 119 
9 NAGARATHINAM 61 F O98032390 I15012557 812.982 10 11.36 17 0.59 11.3 347 126 
10 LAKSHMI.M 45 F O15027025 I15012403 1034.881 1 11.4 31 1.38 9.34 208 248 
11 SAKTHIVEL.R 59 M O14045618 I15012825 793.6378 25 13 29 1.01 9.3 333 277 
12 SHANTHA.P 48 F O14089196   505.3543 5 11.7 16 0.4 9.3 204 215 
13 MYILATHAL 45 F O15029446   580.1847 1 11.2 24 0.57 7.8 64 72 
14 PALANISAMY.V 53 M O15006732 I15012112 581.9402 10 7.5 92 3.5 8.01 222 159 
15 JAYAPRAGASAM.S 66 M O15029035 I15013205 168.8314 16 15.3 14 0.88 6.98 223 135 
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MILD NPDR 
S.NO NAME AGE SEX OP NO. IP NO. 
VEGF 
LEVEL 
DURATION HB 
% 
UREA CREATININE 
HBAIC% 
RBS FBS 
(YEARS) (mg/dl) (mg/dl) (mg/dl) (mg/dl) 
16 SUBBULU.R 72 M O14068986 I14031004 403.4314 10 8.9 27.57 4.24 5.7 163 132 
17 MANI.C 50 M O15001719 I15001508 453.3152 20 9.3 12.02 0.95 7.71 362 151 
18 PALANISAMY.S 65 M O15010964 I15004873 1000.285 10 11.6 61 1.9 9.9 407 248 
19 PADMAVATHY.S 55 F O15012120 I15005403 196.2381 6 12.7 23 0.55 11.78 361 265 
20 KRISHNAVENI 48 F O15009271 I15004281 956.1171 15 10.8 42 0.55 11.38 274 139 
21 BANNARI.S 45 M O15012531 I15005657 485.0806 4 14.4 15 0.76 13.9 181 159 
22 GOVINDASAMY.K 69 M O15016138 I15007383 444.5504 12 9 31 0.57 8.3 123 86 
23 JAMES 58 M O140011081 I14004500 509.3276 20 12.9 32 0.65 6.1 142 124 
24 CHANDRASEKAR 58 M O12000557 I15012650 674.3131 25 11.7 31 1.07 10.37 253 128 
25 GOKILAMANI.P 60 F O15020910 I15009536 686.2036 1 9.8 58 1.87 10.06 296 290 
26 THIRUMOORTHI 65 M O13009631 I15013554 1296.156 36 8.9 69 2.91 6.35 229 96 
27 MUTHUSAMY 64 M O11076842 I15014123 738.3067 3 14.6 48 1.12 12.42 251 213 
28 VEERAI.V 67 M O15019783 I15014475 451.136 8 12.6 16 0.94 12.5 261 386 
29 MANIMEGALAI 55 F O15037100 I15016935 1190.554 15 7.7 27 1.11 11.74 287 110 
30 GOVINDARAJ 47 M O15031530 I15014258 507.3442 7 14.8 16 0.72 7.63 146 148 
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MODERATE NPDR 
 
S.NO 
 
NAME 
 
AGE 
 
SEX 
 
OP NO. 
 
IP NO. 
 
VEGF 
LEVEL 
 
DURATION 
(YEARS) 
HB 
% 
 
UREA CREATININE 
HBAIC% 
RBS FBS 
(mg/dl) (mg/dl) (mg/dl) (mg/dl) 
31 MARATHAL.M 65 F O14081044 I14034062 505.3543 4 11.4 11.21 0.47 11.76 303 167 
32 RAMASWAMY 50 M O14082745 I14034990 693.5164 8 10.5 37 1.25 10.74 220 196 
33 THANALAKSHMI.G 64 F O13071937 I14035057 519.1464 10 12.2 7 0.4 11.42 210 186 
34 SOWKIT ALI 55 M O15010400 I15004689 461.9528 2 6.9 49.59 1.14 5.9 193 121 
35 DURAISAMY.P.S 49 M O15005411 I15005133 612.6858 1 15.8 22 0.76 9.29 176 191 
36 PALINISAMY.R 58 M O15000162   374.3529 10 9.9 128 4.77 7.19 176 191 
37 RAMASWAMY.C 70 M O15011471 I15005131 848.7637 15 11.4 28 0.8 8.5 263 207 
38 GOVINARAJU 50 M O14043599 I15005529 294.7695 3 15.1 18 0.74 10.23 119 126 
39 ABUL KATHAR.K.S 70 M O15009721 I15006526 671.3031 7 14 23 0.5 9.8 255 165 
40 SARASWATHY 56 F O10092419   286.194 20 10.2 39 1.24 9.1 102 81 
41 SELLAMMAL 65 F O15009725 I15006832 1119.566 10 7 52 1.04 11.2 189 158 
42 RAJENDRAN 52 M O15018124 I15008335 743.676 10 12 47 2.02 10.32 296 217 
43 VELUSAMY.P 55 M O0019018 I15008677 61.5702 19 14.2 25 0.66 10.04 287 137 
44 MANOHARAN 
 
M O06065460 I06031533 677.308 12 10.5 28 1.2 11.02 202 140 
45 GOVINDAN.K 67 M O15015004 I15006909 314.312 10 12.8 26 0.88 7.56 120 134 
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SEVERE NPDR 
S.NO 
 
NAME 
 
AGE 
 
SEX 
 
OP NO. 
 
IP NO. 
 
VEGF 
LEVEL 
 
DURATION 
(YEARS) 
HB 
% 
 
UREA CREATININE 
HBAIC% 
RBS FBS 
(mg/dl) (mg/dl) (mg/dl) (mg/dl) 
46 MUTHUKUMARASAMY 42 M O12053890 I14033043 665.2369 12 12 14.02 1.21 11.84 282 173 
47 PADMANABHAN.A 60 M O14078228   428.895 5 10 26.17 2.93 6.5 196 125 
48 MANI.R 47 M O14080175 I14033629 751.6404 10 9.8 35.98 0.98 15.05 228 196 
49 GANAPATHI.P 54 M O14084535 I14035773 856.5545 8 12.3 28.79 0.81 12.01 388 95 
50 RAMACHANDRAN 61 M O14085841 I14036283 8.948788 5 15.1 14.99 0.89 9.85 215 225 
51 SUBRAMANIAN 60 M O08079840 I15004440 113.7779 20 11.4 134 3.64 12.2 263 120 
52 PADMANABHAN.P 60 M O15023416 I15010628 401.0616 10 10.9 52 1.07 15.8 361 244 
53 SHANMUGAM.K 70 M O15026484 I15012142 904.3442 15 9.1 19 0.93 7.6 130 162 
54 ANAND.S 54 M O15027347 I1501209 602.6125 8 12.1 25 0.7 8.86 239 167 
55 GOPAL.G 65 M O15026970 I15012370 831.718 15 11.8 31 0.84 5.39 148 133 
56 MANIVENTHAN.S 47 M O14085698 I14036238 241.3616 4 9.8 33.64 3.7 5.77 178 127 
57 RAJAMANICKAM.A 58 M O15002053   244.4577 12 11.2 38 0.57 9.2 321 294 
58 ROCHAYAN 52 M O15016252 I15007458 702.175 9 8.2 17 0.6 15 190 202 
59 KALAMANI 64 F O10035485 I15015630 779.9649 30 9.4 21 0.79 11 125 122 
60 VIJAYAN 45 M O08017551 I15018263 428.695 16 11 17 1.1 9.1 180 110 
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PDR 
S.NO NAME AGE SEX OP NO. IP NO. 
VEGF 
LEVEL 
DURATION 
(YEARS) 
HB 
% 
UREA CREATININE 
HBAIC% 
RBS FBS 
(mg/dl) (mg/dl) (mg/dl) (mg/dl) 
61 SHANMUGAM.V.M 61 M O12093838 I14032919 117.611 11 11.4 42 1.26 11.14 155 133 
62 GIRIJA 64 F O14034590 I14035236 325.198 10 10.3 59 1.32 10.1 200 291 
63 DHANUSKODI.F 41 M O13022843 I15005699 693.516 9 12.8 31 0.61 11.6 312 110 
64 KALIMUTHU.P 74 M O15011620 I15005151 455.486 14 8.4 100 3.24 13.2 251 133 
65 RENUKA DEVI 57 F O11089002 I13029734 341.163 18 11.8 38 0.98 7.8 207 143 
66 RAMASAMY.M.V 64 M O14074976 I15006925 489.191 3 11.3 44 1.96 7.2 183 111 
67 NAGALINGAM.K.S 52 M O15020630 I15009400 262.704 12 10.4 43 2.23 7.7 194 142 
68 MOHAN.S.N 55 M O08061190 I15010893 1029.94 15 11.2 56 1.96 11.1 261 198 
69 RAJAMANI.A 55 M O150050322 I15011040 478.862 8 14.3 25 0.53 10.6 286 235 
70 PANCHAKALYANI 65 F O14084955 I14035872 779.965 1 8.9 112 2.99 8.49 224 117 
71 GOVINDASAMY.M 70 M O96000653 I10015283 464.093 20 12.4 19 0.81 7.5 186 118 
72 MARIMUTHU.K 65 M O12035212   396.294 20 11.4 31 1.7 7.8 145 109 
73 MUTHUSAMY.M 57 M O14040537   196.238 4 10.6 64 2.59 9.6 185 104 
74 SUKUMAR 42 M O13074323 I15018487 271.621 6 12.3 63.6 11.63 6.9 150 108 
75 PAPPATHY 56 F O14052771 I14021935 1145.32 3 11.9 10 1.6 9.2 190 133 
